menu search

Inhibikase therapeutics to report fourth quarter and full-year 2022 financial results on march 31, 2023

BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmac...

March 23, 2023, 5:15 pm

Biohaven (bhvn) acquires dual inhibitor for brain disorders

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical ...

March 23, 2023, 12:13 pm

Nuvalent to present alkove-1 trial in progress poster for nvl-655 at the european lung cancer congress (elcc 2023)

CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating preci...

March 23, 2023, 6:30 am

Deciphera pharmaceuticals: intrigue phase 3 shows substantial benefit

Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltini...

March 18, 2023, 5:21 am

Predictive oncology and cancer research horizons partner up to pursue development of cancer drugs

Predictive Oncology Inc. (NASDAQ:POAI) and Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cance...

March 17, 2023, 9:23 am

Why is histogen (hsto) stock up 37% today?

Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhi...

March 17, 2023, 8:37 am

Celcuity to present preclinical data on therapeutic effects of gedatolisib in gynecological cancer models at aacr annual meeting 2023

MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted...

March 15, 2023, 7:35 pm

Kinnate biopharma inc. to report first clinical data for its investigational pan-raf inhibitor, exarafenib (kin-2787), in an oral presentation at the aacr 2023 annual meeting

SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision onco...

March 14, 2023, 6:09 pm

Nuvalent to present new preclinical data on alk-selective inhibitor nvl-655 at aacr annual meeting 2023

CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating preci...

March 14, 2023, 5:59 pm

Aptose to report fourth quarter and full year 2022 financial results and hold conference call on thursday, march 23, 2023

SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology compan...

March 9, 2023, 4:05 pm

Tx rx systems to appear at iwce 2023 exhibit hall

ANGOLA, N.Y., March 09, 2023 (GLOBE NEWSWIRE) — TX RX Systems, an industry leader in the Land Mobile Radio (LMR) market, is pleased to announce the ...

March 9, 2023, 3:51 pm

Exchange rate has positive effect on australian gold industry – surbiton

Although US dollar gold prices declined sharply during February to the lowest figures for almost two years, Australian gold producers were broadly shi...

March 6, 2023, 9:59 am

Stable cad plaque morphology improved by pcsk9 inhibitors: yellow iii

Intensified LDL-lowering upped fibrous cap thickness on OCT and cut lipid burden on NIRS. Next up: biomarkers to predict effects. Read Full Story at s...

March 4, 2023, 9:59 pm

Pd-1/pd-l1 inhibitors market to record a cagr of 9.6% & to reach a valuation of usd 123.3 billion by 2033 – exclusive report by future market insights, inc.

Increasing Government Cancer-fighting Measures, Growing Healthcare Expenses, and Increased Public Awareness are anticipated to Propel the Industry Ahe...

March 3, 2023, 11:30 am

Pliant therapeutics' bexotegrast shows promise for idiopathic pulmonary fibrosis

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related d...

March 3, 2023, 10:48 am

Fmls23 has officially kicked off – dates, venue and more

The Finance Magnates London Summit (FMLS) will be returning for its 11th year, returning on November 20-22, 2023 at Old Billingsg...

March 1, 2023, 10:50 am

Cogent biosciences: bezuclastinib's potential in treating gastrointestinal stromal tumors

Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointesti...

February 28, 2023, 2:17 am

Revolution medicines reports fourth quarter and full year 2022 financial results and update on corporate progress

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional...

February 27, 2023, 9:05 pm


Search within

Pages Search Results: